Journal for Malaria Researchers, but with articles which are adaptable to other areas of research, for example some interesting methods papers on how to design, set up a lab, do stats and assessment in a Vaccine trial.
Saved once (save)Bookmarked by Tamzin Furtado on 23 Aug 2011
The Malaria Vectored Vaccines Consortium (MVVC) is a partnership of four African and four European institutions. It has two related objectives:
To develop a malaria vaccine for use by populations where malaria is endemic
Saved once (save)Bookmarked by The Editorial Team on 29 Feb 2012
DRAFT v0.8 (Mar 03, 2020)Possible Enhanced Disease in Vaccinees Following Exposure to Live Virus: Considerations for Preclinical Studies and Early Clinical Trials in the Context of Developing a COVID-19 Vaccine
A new class of broadly neutralizing antibodies that target the glycan loop of Zika virus envelope proteinby Qu et al.
Results showed in this article have strong implications for developing anti-ZIKV vaccines and therapeutic mAbs.
A yellow fever–Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in miceby Kum et al.
The authors of this study report the engineering of a chimeric virus vaccine candidate (YF-ZIKprM/E) by replacing the antigenic surface glycoproteins and the capsid anchor of YFV-17D with those of a prototypic Asian lineage ZIKV isolate.
4 EU-funded Zika consortia met in Marseille during the International Symposium to discuss a common strategy for vaccine developmentby ZIKAlliance
Successful technology transfer of a Zika vaccine developed by Institut Pasteur Shanghai-Chinese Academy of Sciences (IPS-CAS) to Chongqing Zhifei Biological Products Co., Ltd.by ZIKAlliance
Institut Pasteur Shanghai-Chinese Academy of Sciences (IPS-CAS), a partner of the ZIKAlliance consortium, announced that it has entered into a collaborative research agreement with Chongqing Zhifei Biological Products Stock Co., Ltd. (Zhifei) for the clinical studies and commercialization of a recombinant Zika virus subunit vaccine developed by IPS-CAS.
Analysis of potential dengue vaccine impact in Yucatán Mexico.
A phase 3, randomised, observer-masked, placebo-controlled trial of a new tetravalent vaccine against dengue fever. Abstract Background: An estimated 100 million people have symptomatic dengue infection every year. This is the first report of a phase 3 vaccine efficacy trial of a candidate dengue vaccine. We aimed to assess the efficacy of the CYD dengue vaccine against symptomatic, virologically confirmed dengue in children. Methods: We did an observer-masked, randomised controlled, multicentre, phase 3 trial in five countries in the Asia-Pacific region. Between June 3, and Dec 1, 2011, healthy children aged 2—14 years were randomly assigned (2:1), by computer-generated permuted blocks of six with an interactive voice or web response system, to receive three injections of a recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV), or placebo, at months 0, 6, and 12. Randomisation was stratified by age and site. Participants were followed up until month 25. Trial staff responsible for the preparation and administration of injections were unmasked to group allocation, but were not included in the follow-up of the participants; allocation was concealed from the study sponsor, investigators, and parents and guardians. Our primary objective was to assess protective efficacy against symptomatic, virologically confirmed dengue, irrespective of disease severity or serotype, that took place more than 28 days after the third injection. The primary endpoint was for the lower bound of the 95% CI of vaccine efficacy to be greater than 25%. Analysis was by intention to treat and per procotol. This trial is registered with ClinicalTrials.gov, number NCT01373281. Findings: We randomly assigned 10 275 children to receive either vaccine (n=6851) or placebo (n=3424), of whom 6710 (98%) and 3350 (98%), respectively, were included in the primary analysis. 250 cases of virologically confirmed dengue took place more than 28 days after the third injection (117 [47%] in the vaccine group and 133 [53%] in the control group). The primary endpoint was achieved with 56·5% (95% CI 43·8—66·4) efficacy. We recorded 647 serious adverse events (402 [62%] in the vaccine group and 245 [38%] in the control group). 54 (1%) children in the vaccine group and 33 (1%) of those in the control group had serious adverse events that happened within 28 days of vaccination. Serious adverse events were consistent with medical disorders in this age group and were mainly infections and injuries. Interpretation: Our findings show that dengue vaccine is efficacious when given as three injections at months 0, 6, and 12 to children aged 2—14 years in endemic areas in Asia, and has a good safety profile. Vaccination could reduce the incidence of symptomatic infection and hospital admission and has the potential to provide an important public health benefit.
Decline in Diarrhea Mortality and Admissions after Routine Childhood Rotavirus Immunization in Brazil: A Time-Series Analysisby Jai K Das
In 2006, Brazil began routine immunization of infants <15 wk of age with a single-strain rotavirus vaccine. The authors in this paper evaluated whether the rotavirus vaccination program was associated with declines in childhood diarrhea deaths and hospital admissions by monitoring disease trends before and after vaccine introduction in all five regions of Brazil with varying disease burden and distinct socioeconomic and health indicators.